Moreover, we found that our novel tetracyclic derivative, BC-N102 suppressed tumorigenesis via inhibition of ER/Akt/PI3K/ERK/CDK2/4, and induced time-course G0/G1 cell cycle arrest of human breast cancer cells. Here, CDK2 is linked to breast carcinoma.